Dr. Alessia Muzi | Immunology | Women Researcher Award
Principal investigator | Takis srl | Italy
Dr. Alessia Muzi is an accomplished Italian scientist and Principal Investigator at Takis Srl, leading pioneering research in oncology, monoclonal antibody engineering, and translational biotechnology. With over 20 years of experience, she has contributed significantly to therapeutic antibody development, vaccine innovation, and cancer immunotherapy. She holds a Ph.D. in Neurosciences from the University of Sacred Heart “Agostino Gemelli” and advanced degrees in Medical Biotechnology and Regulatory Medicine from the Universities of Rome “Tor Vergata” and “Sapienza.” As Head of the Monoclonal Antibody Laboratory at Takis, Dr. Muzi oversees cutting-edge projects focused on recombinant protein design and tumor-targeting antibodies. Her research bridges molecular biology and clinical applications, aiming to enhance the efficacy of cancer treatments and immunotherapies. Recipient of the FISA-2022-00899 Award for bispecific antibody development, she has co-authored 33 publications with an h-index of 20 and 1,121 citations across 1,018 documents. Dr. Muzi’s scientific leadership, regulatory expertise, and commitment to translational medicine have established her as a leading figure in Italian biomedical innovation and a driving force in advancing therapeutic strategies for oncology and infectious diseases.
Profile: Scopus | ORCID
Featured Publications
Novel Humanized Anti-HER3 Antibodies: Structural Characterization and Therapeutic Activity. (2025). Antibodies. Cited by 12.
Isolation and Characterization of Neutralizing Monoclonal Antibodies Against SARS-CoV-2 Spike Protein. (2024). Antibodies. Cited by 25.
A Linear DNA Vaccine Candidate Encoding SARS-CoV-2 RBD in Domestic Cats. (2023). Mol Ther Methods Clin Dev. Cited by 9.
A First-in-Human Trial of COVID-eVax DNA Vaccine. (2022). Mol Ther. Cited by 40.
Persistent B Cell Memory After SARS-CoV-2 Vaccination. (2022). Cell Host Microbe. Cited by 58.
COVID-eVax: Electroporated DNA Vaccine Candidate Encoding SARS-CoV-2 RBD. (2022). Mol Ther. Cited by 65.
The Nuts and Bolts of SARS-CoV-2 Spike RBD Heterologous Expression. (2021). Biomolecules. Cited by 33.